Samuel Asfaha

Samuel Asfaha

Auto-generated profile, based on publicly available information

Samuel Asfaha

Department of Medicine, University of Western Ontario, London, Ontario, Canada.

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Cell
Verified
Journal Article
Closed access
DWDaniel L. Worthley
Daniel L. Worthley
MCMichael Churchill
Michael Churchill
JCJocelyn T. Compton
Jocelyn T. Compton
YTYagnesh Tailor
Yagnesh Tailor
MRMeenakshi Rao
Meenakshi Rao
TWTimothy Wang
Timothy Wang

1 January 2017 in Cancer Cell
Verified
Journal Article
Closed access
YHYoku Hayakawa
Yoku Hayakawa
KSKosuke Sakitani
Kosuke Sakitani
MKMitsuru Konishi
Mitsuru Konishi
SASamuel Asfaha
Samuel Asfaha
RNRyota Niikura
Ryota Niikura
TWTimothy Wang
Timothy Wang

1 January 2012 in Cancer Cell
Verified
Journal Article
Closed access
MQMichael Quante
Michael Quante
GBGovind Bhagat
Govind Bhagat
JAJulian A. Abrams
Julian A. Abrams
FMFrederic Marache
Frederic Marache
PGPamela Good
Pamela Good
TWTimothy Wang
Timothy Wang

3 February 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CWC. Benedikt Westphalen
C. Benedikt Westphalen
SASamuel Asfaha
Samuel Asfaha
YHYoku Hayakawa
Yoku Hayakawa
YTYoshihiro Takemoto
Yoshihiro Takemoto
DLDana J. Lukin
Dana J. Lukin
TWTimothy Wang
Timothy Wang
Doublecortin-like kinase 1 protein (DCLK1) is a gastrointestinal tuft cell marker that has been proposed to identify quiescent and tumor growth–sustaining stem cells. DCLK1+ tuft cells are increased in inflammation-induced carcinogenesis; however, the role of these cells within the gastrointestinal epithelium and their potential as cancer-initiating cells are poorly understood. Here, using a BAC-CreERT–dependent genetic lineage–tracing strategy, we determined that a subpopulation of DCLK1+ cells is extremely long lived and possesses rare stem cell abilities. Moreover, genetic ablation of Dclk1 revealed that DCLK1+ tuft cells contribute to recovery following intestinal and colonic injury. Surprisingly, conditional knockdown of the Wnt regulator APC in DCLK1+ cells was not sufficient to drive colonic carcinogenesis under normal conditions; however, dextran sodium sulfate–induced (DSS-induced) colitis promoted the development of poorly differentiated colonic adenocarcinoma in mice lacking APC in DCLK1+ cells. Importantly, colonic tumor formation occurred even when colitis onset was delayed for up to 3 months after induced APC loss in DCLK1+ cells. Thus, our data define an intestinal DCLK1+ tuft cell population that is long lived, quiescent, and important for intestinal homeostasis and regeneration. Long-lived DCLK1+ cells maintain quiescence even following oncogenic mutation, but are activated by tissue injury and can serve to initiate colon cancer.

1 November 1996 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BRB K Reuter
B K Reuter
SAS Asfaha
S Asfaha
ABA Buret
A Buret
KSK A Sharkey
K A Sharkey
JWJ L Wallace
J L Wallace
Cyclooxygenase type 1 is constitutively expressed and accounts for synthesis of prostaglandins in the normal gastrointestinal tract. Cyclooxygenase-2 is expressed at sites of inflammation. Selective inhibitors of cyclooxygenase-2 have been suggested to spare gastrointestinal prostaglandin synthesis, and therefore lack the ulcerogenic effects associated with standard nonsteroidal antiinflammatory drugs. However, the effects of cyclooxygenase-2 inhibitors on inflamed gastrointestinal mucosa have not been examined. We examined cyclooxygenase-2 mRNA and protein expression before and after induction of colitis in the rat, the contribution of cyclooxygenase-2 to colonic prostaglandin synthesis during colitis and the effects of selective inhibitors of cyclooxygenase-2 on colonic injury in this model. Cyclooxygenase-2 mRNA expression increased three to sixfold during the period 24 h to 1 wk after induction of colitis, with marked increases in cyclooxygenase-2 protein expression in the lamina propria and muscularis of the colon during colitis. Cyclooxygenase-1 expression (mRNA and protein) was not affected by the induction of colitis. The prostaglandins produced during colitis were largely derived from cyclooxygenase-2. Treatment with selective cyclooxygenase-2 inhibitors resulted in exacerbation of colitis, with perforation occurring when the compounds were administered for a week. These studies demonstrate that suppression of cyclooxygenase-2 can result in exacerbation of inflammation-associated colonic injury.

1 December 2015 in Cancer Cell
Verified
Journal Article
Closed access
YHYoku Hayakawa
Yoku Hayakawa
HAHiroshi Ariyama
Hiroshi Ariyama
JSJitka Stancikova
Jitka Stancikova
KSKosuke Sakitani
Kosuke Sakitani
SASamuel Asfaha
Samuel Asfaha
TWTimothy Wang
Timothy Wang